TY - JOUR
T1 - A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children
AU - Karron, Ruth A.
AU - Wright, Peter F.
AU - Newman, Frances K.
AU - Makhene, Mamodikoe
AU - Thompson, Juliette
AU - Samorodin, Roberta
AU - Wilson, Modena H.
AU - Anderson, Edwin L.
AU - Clements, Mary Lou
AU - Murphy, Brian R.
AU - Belshe, Robert B.
N1 - Funding Information:
Center for Immunization Research, Department ofInternational Health, School ofHygiene and Public Health, Departments ofPediatrics and Medicine, School ofMedicine, Johns Hopkins University, Baltimore, and Laboratory ofInfectious Diseases, National Institute ofAllergy and Infectious Diseases, National Institutes ofHealth, Bethesda, Maryland; Vaccine Evaluation Unit, Department ofPediatrics, Vanderbilt University School ofMedicine, Nashville, Tennessee; Center for Vaccine Development, Division ofInfectious Diseases, Departments ofInternal Medicine and Pediatrics, Saint Louis University, and St. Louis VA Medical Center, St. Louis, Missouri
Funding Information:
Financial support: National Institutes of Health (AI-15095, AI-05051, and AI-05050).
PY - 1995/12
Y1 - 1995/12
N2 - The safety, infectivity, immunogenicity, and phenotypic stability of the cold-passaged (cp) candidate vaccine cp-45, a cold-adapted (ca), temperature-sensitive (ts) mutant of the J8 strain of human parainfluenza virus type 3 (HPIV-3), was evaluated in 114 children 6 months to 10 years old in a randomized, placebo-controlled, double-blind trial. The cp-45 vaccine was well tolerated when given intranasally to parainfluenza virus type 3 (PIV-3)-seropositive and -seronegative children. With 104or 105TCID50of cp-45 vaccine, 86% of seronegative vaccinees were infected, 83% of whom shed virus at a mean peak titer of 102.2pfu/mL. Virus present in respiratory specimens retained the ts phenotype, and each of 86 PIV-3 isolates tested retained both the ca and ts phenotypes. One dose of 105TCID50of vaccine induced a serum hemagglutination-inhibiting antibody response in 81% of vaccinees; the geometric mean titer was 1:32. These studies indicate that the cp-45 HPIV-3 vaccine is satisfactorily attenuated, infectious, immunogenic, and phenotypically stable and merits further evaluation in infants and young children.
AB - The safety, infectivity, immunogenicity, and phenotypic stability of the cold-passaged (cp) candidate vaccine cp-45, a cold-adapted (ca), temperature-sensitive (ts) mutant of the J8 strain of human parainfluenza virus type 3 (HPIV-3), was evaluated in 114 children 6 months to 10 years old in a randomized, placebo-controlled, double-blind trial. The cp-45 vaccine was well tolerated when given intranasally to parainfluenza virus type 3 (PIV-3)-seropositive and -seronegative children. With 104or 105TCID50of cp-45 vaccine, 86% of seronegative vaccinees were infected, 83% of whom shed virus at a mean peak titer of 102.2pfu/mL. Virus present in respiratory specimens retained the ts phenotype, and each of 86 PIV-3 isolates tested retained both the ca and ts phenotypes. One dose of 105TCID50of vaccine induced a serum hemagglutination-inhibiting antibody response in 81% of vaccinees; the geometric mean titer was 1:32. These studies indicate that the cp-45 HPIV-3 vaccine is satisfactorily attenuated, infectious, immunogenic, and phenotypically stable and merits further evaluation in infants and young children.
UR - http://www.scopus.com/inward/record.url?scp=0028837548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028837548&partnerID=8YFLogxK
U2 - 10.1093/infdis/172.6.1445
DO - 10.1093/infdis/172.6.1445
M3 - Article
C2 - 7594701
AN - SCOPUS:0028837548
SN - 0022-1899
VL - 172
SP - 1445
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 6
ER -